Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Achieve Life Sciences Inc (NQ: ACHV )

5.930 +0.020 (+0.34%)
Streaming Delayed Price Updated: 11:18 AM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Achieve Life Sciences Inc

< Previous 1 2 Next >
Achieve Life Sciences Announces Proposed Underwritten Public Offering
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Regulatory Compliance
Exposures Death Legal Product Safety
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
Exposures COVID-19 Death Intellectual Property
Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization... 
From Achieve Life Sciences, Inc.
Via AccessWire
Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property Product Safety
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, WA and VANCOUVER, BC /... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.